Analysts Set Medpace Holdings, Inc. (NASDAQ:MEDP) PT at $380.00

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned an average rating of “Hold” from the eleven research firms that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $380.56.

Several research analysts recently issued reports on the company. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and lowered their target price for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. UBS Group downgraded shares of Medpace from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, Redburn Atlantic began coverage on shares of Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock.

Medpace Trading Up 0.0 %

MEDP stock opened at $337.82 on Friday. The firm has a 50-day moving average price of $339.76 and a 200-day moving average price of $372.60. The stock has a market capitalization of $10.50 billion, a P/E ratio of 29.58, a price-to-earnings-growth ratio of 1.87 and a beta of 1.37. Medpace has a 12 month low of $268.80 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. The company had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.22 earnings per share. As a group, equities analysts predict that Medpace will post 11.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Stone House Investment Management LLC bought a new stake in shares of Medpace during the 3rd quarter worth $33,000. Ashton Thomas Securities LLC purchased a new position in shares of Medpace in the third quarter worth about $37,000. DT Investment Partners LLC bought a new stake in shares of Medpace in the second quarter valued at approximately $41,000. Capital Performance Advisors LLP purchased a new stake in shares of Medpace during the third quarter worth $46,000. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in Medpace during the 2nd quarter worth about $52,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.